4//SEC Filing
Armour Alison A. 4
Accession 0001104659-18-074356
CIK 0001235007other
Filed
Dec 20, 7:00 PM ET
Accepted
Dec 21, 12:53 PM ET
Size
32.2 KB
Accession
0001104659-18-074356
Insider Transaction Report
Form 4
ENDOCYTE INCECYT
Armour Alison A.
Chief Medical Officer
Transactions
- Disposition to Issuer
Common Stock
2018-12-21$24.00/sh−72,253$1,734,072→ 0 total - Disposition to Issuer
Common Stock
2018-12-21$24.00/sh−5,000$120,000→ 0 total - Disposition to Issuer
Common Stock
2018-12-21$24.00/sh−5,000$120,000→ 0 total - Disposition to Issuer
Common Stock
2018-12-21$24.00/sh−20,000$480,000→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2018-12-21$18.84/sh−25,000$471,000→ 0 totalExercise: $5.16Exp: 2025-07-31→ Common Stock (25,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2018-12-21$21.84/sh−39,999$873,578→ 0 totalExercise: $2.16Exp: 2027-02-02→ Common Stock (39,999 underlying) - Gift
Common Stock
2018-12-20−10,500→ 139,753 total - Gift
Common Stock
2018-12-20+10,500→ 10,500 total(indirect: By daughter) - Disposition to Issuer
Common Stock
2018-12-21$24.00/sh−10,500$252,000→ 0 total(indirect: By daughter) - Disposition to Issuer
Common Stock
2018-12-21$24.00/sh−15,000$360,000→ 0 total - Disposition to Issuer
Common Stock
2018-12-21$24.00/sh−22,500$540,000→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2018-12-21$20.82/sh−45,788$953,306→ 0 totalExercise: $3.18Exp: 2026-02-04→ Common Stock (45,788 underlying) - Disposition to Issuer
Stock Option (right to buy)
2018-12-21$20.99/sh−45,000$944,550→ 0 totalExercise: $3.01Exp: 2028-02-08→ Common Stock (45,000 underlying)
Footnotes (11)
- [F1]Represents a gift of 10,500 shares by the reporting person to her daughter, who shares the reporting person's household.
- [F10]This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 2, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
- [F11]This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 8, 2019. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
- [F2]Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes.
- [F3]This restricted stock unit ("RSU") award, which originally consisted of 20,000 RSUs and of which 15,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on July 31, 2016 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
- [F4]This RSU award, which originally consisted of 10,000 RSUs and of which 5,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 4, 2017 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
- [F5]This RSU award, which originally consisted of 20,000 RSUs and of which 5,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 2, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
- [F6]This RSU award, which originally consisted of 40,000 RSUs and of which 20,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/2 annually over a period of 2 years beginning on October 4, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
- [F7]This RSU award provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 8, 2019 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
- [F8]This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on July 31, 2016. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
- [F9]This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 4, 2017. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
Documents
Issuer
ENDOCYTE INC
CIK 0001235007
Entity typeother
Related Parties
1- filerCIK 0001646726
Filing Metadata
- Form type
- 4
- Filed
- Dec 20, 7:00 PM ET
- Accepted
- Dec 21, 12:53 PM ET
- Size
- 32.2 KB